Efficacy and safety of ulipristal acetate in treating uterine fibroids: A review of clinical outcomes.

Smita Cheed*

Division of Pathology, University of Edinburgh, UK

Introduction

Ulipristal acetate (UPA) has emerged as an effective and well-tolerated treatment option for uterine fibroids, offering significant benefits in terms of symptom control and fibroid size reduction [1]. UPA is a selective progesterone receptor modulator (SPRM) that works by inhibiting progesterone activity, leading to a reduction in fibroid volume and improvement in related symptoms such as heavy menstrual bleeding and pelvic pain [2]. Several clinical trials have evaluated the efficacy and safety of UPA in treating uterine fibroids, with promising results [3].

UPA demonstrated significant reductions in fibroid size, with up to 50% volume reduction reported after three months of treatment [4]. Furthermore, the improvement in symptoms, particularly heavy menstrual bleeding, was substantial, leading to enhanced quality of life for many women. UPA's ability to shrink fibroids also offers a non-surgical alternative to women who wish to avoid or delay surgical procedures such as hysterectomy or myomectomy [5].

UPA has potential safety concerns. The most notable risks include liver enzyme elevations and, in rare cases, liver toxicity [6]. Clinical guidelines recommend monitoring liver function during treatment, with discontinuation if significant abnormalities occur [7]. Additionally, UPA treatment is typically limited to short-term use (up to three months) due to concerns about prolonged use and liver health [8].

Overall, UPA is considered a safe and effective treatment for uterine fibroids, offering a valuable alternative to surgery for many women [9]. While its efficacy in reducing fibroid size and alleviating symptoms is well-documented, ongoing monitoring for liver function and adherence to recommended treatment durations are essential to ensure patient safety. Further studies are needed to assess the long-term effects and potential for extended use [10].

Conclusion

Ulipristal acetate (UPA) has proven to be an effective and safe option for managing uterine fibroids, offering significant improvements in symptom management and fibroid size reduction. Its role as a selective progesterone receptor modulator makes it a promising alternative to surgery, especially for women seeking non-invasive treatment. Clinical studies have demonstrated its ability to reduce fibroid volume and alleviate symptoms such as heavy menstrual bleeding and pelvic pain, leading to enhanced quality of life for many patients.

References

1. Kalampokas T, Kamath M, Boutas I, et al. Ulipristal acetate for uterine fibroids: a systematic review and meta-analysis. Gynecol Endocrinol. 2016;32(2):91-6.
2. Garnock-Jones KP, Duggan ST. Ulipristal acetate: a review in symptomatic uterine fibroids. Drugs. 2017;77:1665-75.
3. Tafi E, Scala C, Leone Roberti Maggiore U, et al. Drug safety evaluation of ulipristal acetate in the treatment of uterine fibroids. Expert Opin Drug Saf. 2015;14(6):965-77.
4. De Gasperis-Brigante C, Singh SS, Vilos G, et al. Pregnancy outcomes following ulipristal acetate for uterine fibroids: a systematic review. J Obstet Gynaecol Can. 2018;40(8):1066-76.
5. Liu JH, Soper D, Lukes A, et al. Ulipristal acetate for treatment of uterine leiomyomas: a randomized controlled trial. Obstet Gynecol. 2018;132(5):1241-51.
6. Ferrero S, Vellone VG, Barra F. Pharmacokinetic drug evaluation of ulipristal acetate for the treatment of uterine fibroids. Expert Opin Drug Metab Toxico. 2018;14(1):107-16.
7. Nagy B, Timár G, Józwiak-Hagymásy J, et al. The cost-effectiveness of ulipristal acetate tablets in treating patients with moderate to severe symptoms of uterine fibroids. Eur J Obstet Gynecol Reprod Biol. 2014;175:75-81.
8. De Milliano I, Van Hattum D, Ket JC, et al. Endometrial changes during ulipristal acetate use: a systematic review. Eur J Obstet Gynecol Reprod Biol. 2017;214:56-64.
9. Rovelli RJ, Cieri-Hutcherson NE, Hutcherson TC. Systematic review of oral pharmacotherapeutic options for the management of uterine fibroids. J Am Pharm Assoc (2003). 2022;62(3):674-82.
10. Croxtall JD. Ulipristal acetate: in uterine fibroids. Drugs. 2012;72:1075-85.

***Correspondence to:** Xiao Shi, Department of gynecology, Zhengzhou University, China. E-mail: xshi@zu.ch.org

Received*:** 22-Aug-2024, Manuscript No. AAGGS-24-154858; ***Editor assigned: 23-Aug-2024, Pre QC No. AAGGS-24-154858(PQ); ***Reviewed*:** 06-Sep-2024, QC No. AAGGS-24-154858; ***Revised:*** 11-Sep-2024, Manuscript No. AAGGS-24-154858(R); ***Published:*** 18-Sep-2024, DOI: 10.35841/aajnnr-8.5.225

Citation: *Cheed S. Efficacy and safety of ulipristal acetate in treating uterine fibroids: A review of clinical outcomes. Gynecol Reprod Endocrinol.2024;8(5):226*